We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Faron Pharmaceuticals Oy | LSE:FARN | London | Ordinary Share | FI4000153309 | ORD NPV (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.50 | -0.42% | 117.50 | 115.00 | 120.00 | 117.50 | 117.50 | 117.50 | 4,573 | 08:00:19 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -28.73M | -0.4177 | -2.81 | 80.82M |
TIDMFARN
RNS Number : 5889G
Faron Pharmaceuticals Oy
30 May 2017
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i) ------------------------------------------------------------------------------------------------- 1. Identity of the issuer or Faron Pharmaceuticals Oy the underlying issuer of existing shares to which voting rights are attached: (ii) ----------------------------------------------------------- ------------------------------------ 2 Reason for the notification (please tick the appropriate box or boxes): ------------------------------------------------------------------------------------------------- An acquisition or disposal of voting rights X ------------------------------------------------------------ ----------------------------------- An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached ------------------------------------------------------------ ----------------------------------- An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments ------------------------------------------------------------ ----------------------------------- An event changing the breakdown of voting rights ------------------------------------------------------------ ----------------------------------- Other (please specify): ---------------------------------------------------------- ----------------------------------- 3. Full name of person(s) City Financial Investment subject to the Company Limited, acting as notification obligation: Investment Manager and Authorised (iii) Corporate Director of the City Financial Absolute Equity Fund ----------------------------------------------------------- ------------------------------------ 4. Full name of shareholder(s) BNY Mellon Trust and Depositary (if different from 3.):(iv) as Trustee to the City Financial Absolute Equity Fund ----------------------------------------------------------- ------------------------------------ 5. Date of the transaction 26 May 2017 and date on which the threshold is crossed or reached: (v) ----------------------------------------------------------- ------------------------------------ 6. Date on which issuer 30 May 2017 notified: ----------------------------------------------------------- ------------------------------------ 7. Threshold(s) that is/are crossed or reached: (vi, vii) 4% ----------------------------------------------------------- ------------------------------------ 8. Notified details: ---------------------------------------------------------------------------------------------------------------------- A: Voting rights attached to shares (viii, ix) ---------------------------------------------------------------------------------------------------------------------- Class/type Situation previous Resulting situation after the of to the triggering triggering transaction shares transaction if possible using the ISIN CODE ----------- ---------------------------------- --------------------------------------------------------------------- Number Number Number Number of % of voting of of of shares voting rights (x) Shares Voting rights Rights ----------- ---------------- ---------------- -------------- -------------------------- ------------------------- Direct Direct Indirect Direct Indirect (xi) (xii) ----------- ------------ ------------ -------------- ------------ ------------ ------------ ----------- 1,105,530 1,140,530 1,140,530 1,105,530 1,105,530 0 3.98% 0 ----------- ---------------- ---------------- -------------- ------------ ------------ ------------ ----------- B: Qualifying Financial Instruments ---------------------------------------------------------------------------------------------------------------------- Resulting situation after the triggering transaction ---------------------------------------------------------------------------------------------------------------------- Type of Expiration Exercise/ Number of voting % of voting financial date Conversion rights that rights instrument (xiii) Period (xiv) may be acquired if the instrument is exercised/ converted. --------------- -------------- -------------------------------- ---------------------------- --------------------- C: Financial Instruments with similar economic effect to Qualifying Financial Instruments (xv, xvi) ---------------------------------------------------------------------------------------------------------------------- Resulting situation after the triggering transaction ---------------------------------------------------------------------------------------------------------------------- Type of Exercise Expiration Exercise/ Number of voting % of voting financial price date Conversion rights instrument rights (xix, instrument (xvii) period refers to xx) (xviii) ------------- -------------- -------------- ---------------- ---------------------------- ----------------------- Nominal Delta ------------- -------------- -------------- ---------------- ---------------------------- ------------ --------- Total (A+B+C) ---------------------------------------------------------------------------------------------------------------------- Number of voting rights Percentage of voting rights ------------------------------------------------- ------------------------------------------------------------------- 1,105,530 3.98% ------------------------------------------------- ------------------------------------------------------------------- 9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: (xxi) ------------------------------------------------------------------------------ The voting rights are managed and controlled by City Financial Investment Company Limited, Investment manager and ACD to the City Financial Absolute Equity Fund. Proxy Voting: ------------------------------------------------------------------------------ 10. Name of the proxy holder: ------------------------------------------------------------- --------------- 11. Number of voting rights proxy holder will cease to hold: ------------------------------------------------------------- --------------- 12. Date on which proxy holder will cease to hold voting rights: ------------------------------------------------------------- --------------- 13. Additional information: ------------------------------------------------------------- --------------- 14. Contact name: Ben Ellenbogen ------------------------------------------------------------- --------------- 15. Contact telephone number: 0207 451 9600 ------------------------------------------------------------- ---------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLXBLFXDEFBBBZ
(END) Dow Jones Newswires
May 30, 2017 09:06 ET (13:06 GMT)
1 Year Faron Pharmaceuticals Oy Chart |
1 Month Faron Pharmaceuticals Oy Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions